Gaps in vision screening for school-aged children uncovered in study

News
Article

A new study found that only a little over half of school-aged children participants underwent vision screening within the past two years, highlighting gaps in eye care access.

Image credit: AdobeStock/DragonImages

(Image credit: AdobeStock/DragonImages)

There is a significant need to identify children who are at risk of preventable loss of vision, according to new research conducted by Boston researchers. Most often these children are part of socioeconomically vulnerable groups who do not have access to vision screening and follow-up care.1 The study was led by first author Isdin Oke, MD, PhD, from the Department of Ophthalmology, Boston Children’s Hospital and Harvard Medical School, Boston.

The authors conducted a cross-sectional study of schoolchildren who ranged in age from 6 to younger than 18 years. The children participated in the National Survey of Children’s Health, which is a nationally representative survey of the noninstitutionalized US pediatric population.2

The investigators recounted that the vision screening questions had been updated in 2021 to facilitate analysis of 3 steps along the vision screening pathway, ie, receipt of screening, referral for eye examination, and establishment of specialty care. The sociodemographic variables included age, sex, race, ethnicity, insurance type, household income, caregiver education level, household generation, and primary household language.

Data were available for 30,173 children. Of those, 18,494 underwent vision screening within the past 2 years and 5,134 had been referred for an eye examination. Most of those referred, ie, 4,823, reported establishing specialty care.

Ethnicity, income, and primary language were found to be factors in children less likely to receive specialized care. “Children identifying as Hispanic, non-Hispanic Asian, or non-Hispanic Black, residing in low-income households, and with a non-English primary household language were less likely to receive screening, more likely to be referred for an eye examination, and less likely to establish care with a specialist. Adolescents, children without health insurance, and children with caregivers with less than high school education were less likely to receive screening and more likely to be referred for an eye examination,” Oke and colleagues reported.

The current approach to vision screening in the US, which the authors describe as a“multifaceted approach and variability in vision screening policies,” may be the reason that children do not receive care to prevent vision loss.3

The authors of this study called for implementation of novel strategies that will improve the ophthalmic communities ability to identify children at greatest risk of preventable vision loss.

References
  1. Oke I, Slopen N, Galbraith AA, Hunter DG, Wu AC. Gaps in the vision screening pathway for school-aged US children. JAMA Ophthalmol.Published online January 25, 2024; doi:10.1001/jamaophthalmol.2023.6316
  2. Ghandour RM, Jones JR, Lebrun-Harris A, et al. The design and implementation of the 2016 National Survey of Children’s Health. Matern Child Health J. 2018;22:10931102. doi:10.1007/s10995-018-2526-x
  3. Wahl MD, Fishman D, Block SS,et al. A comprehensive review of state vision screening mandates for schoolchildren in the United States. Optom Vis Sci. 2021;98:490-499. doi:10.1097/OPX.0000000000001686
Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.